Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Humira biomarker-guided add-on therapy study in partial anti-VEGF responders with wet age-related macular degeneration
MOH_2020-05-25_008971Phase 2Recruiting
- Sponsor
- פרופ' איתי חוברס
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in exudative macular degeneration comparing Humira plus anti-VEGF with Placebo plus anti-VEGF (2 arms). Started May 2020; status: recruiting.
02
Drugs
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on MOH_2020-05-25_008971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-05-25_008971.